Splenomegaly: Difference between revisions

Jump to navigation Jump to search
Line 46: Line 46:
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congestive
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Congestive
! colspan="2" align="center" style="background:#DCDCDC;" |[[Cirrhosis]]<ref name="pmid22710653">{{cite journal |vauthors=Wu Z, Zhou J, Pankaj P, Peng B |title=Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity |journal=Surg Endosc |volume=26 |issue=12 |pages=3557–64 |date=December 2012 |pmid=22710653 |doi=10.1007/s00464-012-2366-5 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Cirrhosis]]<ref name="pmid22710653">{{cite journal |vauthors=Wu Z, Zhou J, Pankaj P, Peng B |title=Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity |journal=Surg Endosc |volume=26 |issue=12 |pages=3557–64 |date=December 2012 |pmid=22710653 |doi=10.1007/s00464-012-2366-5 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Infection]]
* [[Infection]]
* [[Alcohol]]
* [[Alcohol]]
* [[Autoimmunity|Autoimmune]]
* [[Autoimmunity|Autoimmune]]
| align="center" style="background:#F5F5F5;" |Any, more in elderly
| align="center" style="background:#F5F5F5;" |Any, more in elderly
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Hepatitis]]
* [[Hepatitis]]
* [[Alcoholism|Alcohol use]]
* [[Alcoholism|Alcohol use]]
Line 77: Line 77:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Dark [[urine]]
* Dark [[urine]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pancytopenia]]
* [[Pancytopenia]]
* Regenerating nodules of [[Hepatocyte|hepatocytes]]
* Regenerating nodules of [[Hepatocyte|hepatocytes]]
* [[Fibrosis]]
* [[Fibrosis]]
* Deposition of [[connective tissue]] between these nodules
* Deposition of [[connective tissue]] between these nodules
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Small and nodular [[liver]] on [[ultrasound]]
* Small and nodular [[liver]] on [[ultrasound]]
* [[Fibrosis]] on [[liver]] scan
* [[Fibrosis]] on [[liver]] scan
| align="center" style="background:#F5F5F5;" |[[Liver biopsy]]
| align="center" style="background:#F5F5F5;" |[[Liver biopsy]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Hepatic encephalopathy]]
* [[Hepatic encephalopathy]]
* [[Gynecomastia]]
* [[Gynecomastia]]
Line 95: Line 95:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Congestive heart failure|Heart failure]]<ref name="pmid26489162">{{cite journal |vauthors=Gedela M, Khan M, Jonsson O |title=Heart Failure |journal=S D Med |volume=68 |issue=9 |pages=403–5, 407–9 |date=September 2015 |pmid=26489162 |doi= |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Congestive heart failure|Heart failure]]<ref name="pmid26489162">{{cite journal |vauthors=Gedela M, Khan M, Jonsson O |title=Heart Failure |journal=S D Med |volume=68 |issue=9 |pages=403–5, 407–9 |date=September 2015 |pmid=26489162 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Coronary heart disease|Coronary artery disease]]
* [[Coronary heart disease|Coronary artery disease]]
* [[Hypertension|HTN]]
* [[Hypertension|HTN]]
| align="center" style="background:#F5F5F5;" |Elderly
| align="center" style="background:#F5F5F5;" |Elderly
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Smoking]]
* [[Smoking]]
* Sedentary lifestyle
* Sedentary lifestyle
Line 112: Line 112:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Dyspnea]]
* [[Dyspnea]]
* [[Muscle weakness|Weakness]]
* [[Muscle weakness|Weakness]]
Line 126: Line 126:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Normal or low [[ejection fraction]] on [[echocardiography]]
* Normal or low [[ejection fraction]] on [[echocardiography]]
* [[Cardiomegaly]] on [[Chest X-ray|chest x-ray]]
* [[Cardiomegaly]] on [[Chest X-ray|chest x-ray]]
| align="center" style="background:#F5F5F5;" |[[Echocardiography]]
| align="center" style="background:#F5F5F5;" |[[Echocardiography]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pulmonary edema]]
* [[Pulmonary edema]]
* [[Hyponatremia]]
* [[Hyponatremia]]
Line 136: Line 136:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Thrombosis]] of [[portal]], [[Liver|hepatic]], or [[Splenic vein|splenic veins]]<ref name="pmid22481689">{{cite journal |vauthors=Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ |title=Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center |journal=Arq Gastroenterol |volume=49 |issue=1 |pages=69–76 |date=2012 |pmid=22481689 |doi= |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Thrombosis]] of [[portal]], [[Liver|hepatic]], or [[Splenic vein|splenic veins]]<ref name="pmid22481689">{{cite journal |vauthors=Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ |title=Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center |journal=Arq Gastroenterol |volume=49 |issue=1 |pages=69–76 |date=2012 |pmid=22481689 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Thrombosis]]
* [[Thrombosis]]
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Inflammation]]
* [[Inflammation]]
* [[Infection]]
* [[Infection]]
Line 153: Line 153:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Muscle weakness|Weakness]]
* [[Muscle weakness|Weakness]]
*[[Hematemesis]]
*[[Hematemesis]]
Line 164: Line 164:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Dark [[urine]]
* Dark [[urine]]
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Reduced or absent [[blood flow]] on [[Medical ultrasonography|doppler ultrasonography]]
* Reduced or absent [[blood flow]] on [[Medical ultrasonography|doppler ultrasonography]]
| align="center" style="background:#F5F5F5;" |[[Medical ultrasonography|Doppler ultrasonography]]
| align="center" style="background:#F5F5F5;" |[[Medical ultrasonography|Doppler ultrasonography]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Portal hypertension]]
* [[Portal hypertension]]
* [[Esophageal varices]]
* [[Esophageal varices]]
Line 176: Line 176:
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! colspan="2" align="center" style="background:#DCDCDC;" |[[Lymphoma]]<ref name="pmid25131182">{{cite journal |vauthors=Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y |title=Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma |journal=Hematology |volume=20 |issue=4 |pages=203–7 |date=May 2015 |pmid=25131182 |doi=10.1179/1607845414Y.0000000192 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Lymphoma]]<ref name="pmid25131182">{{cite journal |vauthors=Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y |title=Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma |journal=Hematology |volume=20 |issue=4 |pages=203–7 |date=May 2015 |pmid=25131182 |doi=10.1179/1607845414Y.0000000192 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Unknown
* Unknown
* [[Mutation]]
* [[Mutation]]
* [[Infection]]
* [[Infection]]
| align="center" style="background:#F5F5F5;" |Any, most common malignant splenic tumor
| align="center" style="background:#F5F5F5;" |Any, most common malignant splenic tumor
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Epstein Barr virus]]
* [[Epstein Barr virus]]
* Positive family history
* Positive family history
Line 196: Line 196:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Lymphadenopathy]]
* [[Lymphadenopathy]]
* [[Itch|Itching]]
* [[Itch|Itching]]
Line 210: Line 210:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Different [[Histopathology|histopathological]] features based on types and stages
* Different [[Histopathology|histopathological]] features based on types and stages
* [[Reed-Sternberg cell]]
* [[Reed-Sternberg cell]]
* Malignant cells
* Malignant cells
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Peritoneal [[Primary central nervous system lymphoma|lymphomatosis]] on [[Computed tomography|CT scan]]
* Peritoneal [[Primary central nervous system lymphoma|lymphomatosis]] on [[Computed tomography|CT scan]]
| align="center" style="background:#F5F5F5;" |[[Lymph node biopsy]]
| align="center" style="background:#F5F5F5;" |[[Lymph node biopsy]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Immune disorder|Primary immune disorder]]
* [[Immune disorder|Primary immune disorder]]
* Post-[[Organ transplant|transplant]]
* Post-[[Organ transplant|transplant]]
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Leukemia]]<ref name="pmid26614896">{{cite journal |vauthors=Quest GR, Johnston JB |title=Clinical features and diagnosis of hairy cell leukemia |journal=Best Pract Res Clin Haematol |volume=28 |issue=4 |pages=180–92 |date=December 2015 |pmid=26614896 |doi=10.1016/j.beha.2015.10.017 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Leukemia]]<ref name="pmid26614896">{{cite journal |vauthors=Quest GR, Johnston JB |title=Clinical features and diagnosis of hairy cell leukemia |journal=Best Pract Res Clin Haematol |volume=28 |issue=4 |pages=180–92 |date=December 2015 |pmid=26614896 |doi=10.1016/j.beha.2015.10.017 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Unknown
* Unknown
* [[Mutation]]
* [[Mutation]]
* [[Bone marrow]]<nowiki/>infiltration
* [[Bone marrow]]<nowiki/>infiltration
* Ineffective [[hematopoiesis]]
* Ineffective [[hematopoiesis]]
* [[Immunity (medical)|Immune]] mediated
* [[Immunity (medical)|Immune]] mediated
| align="center" style="background:#F5F5F5;" |Elderly, male>female
| align="center" style="background:#F5F5F5;" |Elderly, male>female
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* History of [[Hematological|hematological disorder]]
* History of [[Hematological|hematological disorder]]
* History of [[chemotherapy]] and[[ionizing radiation]]
* History of [[chemotherapy]] and[[ionizing radiation]]
Line 242: Line 241:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pallor]]
* [[Pallor]]
* [[Chloroma|Leukemia cutis]]
* [[Chloroma|Leukemia cutis]]
Line 248: Line 247:
* [[Petechia|Petechiae]]
* [[Petechia|Petechiae]]
* [[Ecchymosis]]
* [[Ecchymosis]]
* [[Fatigue]]
* [[Fatigue]]
* Bone [[tenderness]]
* Bone [[tenderness]]
Line 260: Line 258:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Leukemic blasts
* Leukemic blasts
* Leukoerythroblastic features
* Leukoerythroblastic features
Line 266: Line 264:
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]] + clinical manifestation
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Infection|Infections]] of variable severity
* [[Infection|Infections]] of variable severity
* [[Nerve palsy|Cranial nerve palsy]]
* [[Nerve palsy|Cranial nerve palsy]]
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Polycythemia vera|Polycythemia Vera]]<ref name="pmid23281576">{{cite journal |vauthors=Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH |title=Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage |journal=Eur. J. Haematol. |volume=90 |issue=3 |pages=228–36 |date=March 2013 |pmid=23281576 |doi=10.1111/ejh.12064 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Polycythemia vera|Polycythemia Vera]]<ref name="pmid23281576">{{cite journal |vauthors=Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH |title=Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage |journal=Eur. J. Haematol. |volume=90 |issue=3 |pages=228–36 |date=March 2013 |pmid=23281576 |doi=10.1111/ejh.12064 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Autonomous [[erythrocyte]]<nowiki/>production
* Autonomous [[erythrocyte]]<nowiki/>production
* [[JAK2]]<nowiki/>mutation  
* [[JAK2]]<nowiki/>mutation  
| align="center" style="background:#F5F5F5;" |Mean age >60 years old
| align="center" style="background:#F5F5F5;" |Mean age >60 years old
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
Line 286: Line 284:
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Erythromelalgia]]
* [[Erythromelalgia]]
* [[Chest pain]]
* [[Chest pain]]
Line 304: Line 302:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Elevated normochromic, normocytic [[Red blood cell|RBCs]]
* Elevated normochromic, normocytic [[Red blood cell|RBCs]]
* [[Thrombocytosis]]
* [[Thrombocytosis]]
Line 311: Line 309:
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |WHO criteria for [[Polycythemia vera|PV]]
| align="center" style="background:#F5F5F5;" |WHO criteria for [[Polycythemia vera|PV]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Stroke]]
* [[Stroke]]
* [[Venous thrombosis]]
* [[Venous thrombosis]]
Line 345: Line 343:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Multiple myeloma]]<ref name="pmid3400674">{{cite journal |vauthors=Grieco A, Manna R, Mancini R, Gambassi G |title=Massive hepatomegaly following splenectomy for myeloid metaplasia |journal=Am. J. Med. |volume=84 |issue=4 |pages=797 |date=April 1988 |pmid=3400674 |doi= |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Multiple myeloma]]<ref name="pmid3400674">{{cite journal |vauthors=Grieco A, Manna R, Mancini R, Gambassi G |title=Massive hepatomegaly following splenectomy for myeloid metaplasia |journal=Am. J. Med. |volume=84 |issue=4 |pages=797 |date=April 1988 |pmid=3400674 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Unknown
* Unknown
* [[Mutation]]
* [[Mutation]]
* [[Infection]]
* [[Infection]]
| align="center" style="background:#F5F5F5;" |Any, more in adults
| align="center" style="background:#F5F5F5;" |Any, more in adults
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Exposure to chemicals
* Exposure to chemicals
* [[Radiation therapy|Radiation]]
* [[Radiation therapy|Radiation]]
Line 363: Line 361:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Lymphadenopathy]]
* [[Lymphadenopathy]]
* [[Itch|Itching]]
* [[Itch|Itching]]
Line 376: Line 374:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Hemoglobinuria]]
* [[Hemoglobinuria]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Blast cells
* Blast cells
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]]
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Tumor lysis syndrome]]
* [[Tumor lysis syndrome]]
* [[Infection]]
* [[Infection]]
Line 389: Line 387:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="pmid25611051">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=90 |issue=2 |pages=162–73 |date=February 2015 |pmid=25611051 |doi=10.1002/ajh.23895 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]<ref name="pmid25611051">{{cite journal |vauthors=Tefferi A, Barbui T |title=Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=90 |issue=2 |pages=162–73 |date=February 2015 |pmid=25611051 |doi=10.1002/ajh.23895 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Acquired mutation of ''[[Janus kinase|JAK2]], CALR,'' or ''MPL''
* Acquired mutation of ''[[Janus kinase|JAK2]], CALR,'' or ''MPL''
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, female > male
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, female > male
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Vascular occlusive events and [[Bleeding|hemorrhages]]
* Vascular occlusive events and [[Bleeding|hemorrhages]]
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
Line 403: Line 401:
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Flushing]]
* [[Flushing]]
* [[Erythromelalgia]]
* [[Erythromelalgia]]
Line 417: Line 415:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Increased cellularity
* Increased cellularity
* [[Hyperplasia]] and clustering of [[Megakaryocyte|megakaryocytes]]
* [[Hyperplasia]] and clustering of [[Megakaryocyte|megakaryocytes]]
* [[Bone marrow]] [[Reticular fiber|reticulin]] may be increased with no [[collagen]] [[fibrosis]]
* [[Bone marrow]] [[Reticular fiber|reticulin]] may be increased with no [[collagen]] [[fibrosis]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Splenomegaly]] on abdominal CT
* [[Splenomegaly]] on abdominal CT
* [[VTE]] on spiral chest CT
* [[VTE]] on spiral chest CT
* [[Deep vein thrombosis|DVT]] on [[ultrasound]]
* [[Deep vein thrombosis|DVT]] on [[ultrasound]]
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]]
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Thrombosis]]
* [[Thrombosis]]
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="pmid23514013">{{cite journal |vauthors=Cervantes F, Martinez-Trillos A |title=Myelofibrosis: an update on current pharmacotherapy and future directions |journal=Expert Opin Pharmacother |volume=14 |issue=7 |pages=873–84 |date=May 2013 |pmid=23514013 |doi=10.1517/14656566.2013.783019 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]<ref name="pmid23514013">{{cite journal |vauthors=Cervantes F, Martinez-Trillos A |title=Myelofibrosis: an update on current pharmacotherapy and future directions |journal=Expert Opin Pharmacother |volume=14 |issue=7 |pages=873–84 |date=May 2013 |pmid=23514013 |doi=10.1517/14656566.2013.783019 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Bone marrow]] fibrosis
* [[Bone marrow]] fibrosis
* [[Mutation]] in ''[[Janus kinase|JAK2]], CALR'', or ''MPL''
* [[Mutation]] in ''[[Janus kinase|JAK2]], CALR'', or ''MPL''
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, male> female
| align="center" style="background:#F5F5F5;" |Mean age >60 years old, male> female
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Other [[Myeloproliferative neoplasm|myeloproliferative]]<nowiki/>disorders
* Other [[Myeloproliferative neoplasm|myeloproliferative]]<nowiki/>disorders
* [[Radioactive contamination|Radiation exposure]]
* [[Radioactive contamination|Radiation exposure]]
Line 447: Line 445:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pallor]]
* [[Pallor]]
* [[Bruising]]
* [[Bruising]]
* [[Nodules|Skin nodules]]
* [[Nodules|Skin nodules]]
* [[Nodules|Insert paragraph]]
* [[Nodules|Insert paragraph]]
* [[Fatigue]]
* [[Fatigue]]
* [[Abdominal pain]]
* [[Abdominal pain]]
Line 465: Line 462:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Urine|Dark urine]]
* [[Urine|Dark urine]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Proliferation and [[atypia]] of [[megakaryocytes]]
* Proliferation and [[atypia]] of [[megakaryocytes]]
* Reticulin or [[Collagen|collagen fibrosis]]
* Reticulin or [[Collagen|collagen fibrosis]]
* Hypercellular [[bone marrow]]
* Hypercellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Diffuse bone [[sclerosis]] on [[CT angiography|CT]]
* Diffuse bone [[sclerosis]] on [[CT angiography|CT]]
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]]
| align="center" style="background:#F5F5F5;" |[[Bone marrow examination|Bone marrow biopsy]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Thrombosis]]
* [[Thrombosis]]
* Variable risk for development of [[acute leukemia]]
* Variable risk for development of [[acute leukemia]]
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Splenic tumor|Primary splenic tumors]]<ref name="pmid21810495">{{cite journal |vauthors=Adachi K, Ui M, Nojima H, Takada Y, Enatsu K |title=Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy |journal=Am. J. Surg. |volume=202 |issue=2 |pages=e17–9 |date=August 2011 |pmid=21810495 |doi=10.1016/j.amjsurg.2010.10.002 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Splenic tumor|Primary splenic tumors]]<ref name="pmid21810495">{{cite journal |vauthors=Adachi K, Ui M, Nojima H, Takada Y, Enatsu K |title=Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy |journal=Am. J. Surg. |volume=202 |issue=2 |pages=e17–9 |date=August 2011 |pmid=21810495 |doi=10.1016/j.amjsurg.2010.10.002 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Lymphatic system|Lymphoid]] neoplasms
* [[Lymphatic system|Lymphoid]] neoplasms
* [[Vascular]] neoplasms
* [[Vascular]] neoplasms
| align="center" style="background:#F5F5F5;" |Very rare
| align="center" style="background:#F5F5F5;" |Very rare
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 494: Line 491:
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Lymphadenopathy
* Lymphadenopathy
* Dyspnea
* Dyspnea
Line 508: Line 505:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Urine|Dark urine]]
* [[Urine|Dark urine]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Different histopathologic features depends on the type of tumor
* Different histopathologic features depends on the type of tumor
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Heterogeneous mass in the [[spleen]] on [[ultrasound]]
* Heterogeneous mass in the [[spleen]] on [[ultrasound]]
* Lymphomatous [[Nodule (medicine)|nodules]] and masses on [[Computed tomography|CT scan]]
* Lymphomatous [[Nodule (medicine)|nodules]] and masses on [[Computed tomography|CT scan]]
| align="center" style="background:#F5F5F5;" |[[Biopsy]]
| align="center" style="background:#F5F5F5;" |[[Biopsy]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Metastasis]] to [[liver]]
* [[Metastasis]] to [[liver]]
* Poor prognosis
* Poor prognosis
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Metastasis|Metastatic solid tumors]]<ref name="pmid24172780">{{cite journal |vauthors=Huprikar NA, Kurtz MT, Mount CA |title=Massive splenomegaly and lymphopenia: a unique case of obstructive shock |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=October 2013 |pmid=24172780 |pmc=3822246 |doi=10.1136/bcr-2013-201643 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Metastasis|Metastatic solid tumors]]<ref name="pmid24172780">{{cite journal |vauthors=Huprikar NA, Kurtz MT, Mount CA |title=Massive splenomegaly and lymphopenia: a unique case of obstructive shock |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=October 2013 |pmid=24172780 |pmc=3822246 |doi=10.1136/bcr-2013-201643 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Bone marrow]]<nowiki/>infiltration
* [[Bone marrow]]<nowiki/>infiltration
* Ineffective [[hematopoiesis]]
* Ineffective [[hematopoiesis]]
* [[Immunity (medical)|Immune]] mediated
* [[Immunity (medical)|Immune]] mediated
| align="center" style="background:#F5F5F5;" |Any, more in adults
| align="center" style="background:#F5F5F5;" |Any, more in adults
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Exposure to chemicals
* Exposure to chemicals
* [[Radiation therapy|Radiation]]
* [[Radiation therapy|Radiation]]
Line 540: Line 536:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Petechia|Petechiae]]
* [[Petechia|Petechiae]]
* [[Muscle weakness|Weakness]]
* [[Muscle weakness|Weakness]]
Line 550: Line 546:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Urine|Dark urine]]
* [[Urine|Dark urine]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Blast cells
* Blast cells
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |[[Biopsy]]
| align="center" style="background:#F5F5F5;" |[[Biopsy]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Tumor lysis syndrome]]
* [[Tumor lysis syndrome]]
* [[Infection]]
* [[Infection]]
Line 592: Line 588:
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]]
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]]
! align="center" style="background:#DCDCDC;" |[[Hepatitis]]<ref name="pmid23904062">{{cite journal |vauthors=Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S |title=Hepatitis A in children- clinical course, complications and laboratory profile |journal=Indian J Pediatr |volume=81 |issue=1 |pages=15–9 |date=January 2014 |pmid=23904062 |doi=10.1007/s12098-013-1114-8 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Hepatitis]]<ref name="pmid23904062">{{cite journal |vauthors=Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S |title=Hepatitis A in children- clinical course, complications and laboratory profile |journal=Indian J Pediatr |volume=81 |issue=1 |pages=15–9 |date=January 2014 |pmid=23904062 |doi=10.1007/s12098-013-1114-8 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Infection]]
* [[Infection]]
* [[Autoimmunity|Autoimmune]]
* [[Autoimmunity|Autoimmune]]
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* High risk behaviors
* High risk behaviors
* Close contact
* Close contact
Line 608: Line 604:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Lymphadenopathy]]
* [[Lymphadenopathy]]
* [[Muscle weakness]]
* [[Muscle weakness]]
Line 621: Line 617:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Urine|Dark urine]]
* [[Urine|Dark urine]]
* [[Hematuria]]
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pancytopenia]]
* [[Pancytopenia]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Clinical manifestation + lab tests
| align="center" style="background:#F5F5F5;" |Clinical manifestation + lab tests
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Depends on etiology
* Depends on etiology
* [[Encephalomyelitis]]
* [[Encephalomyelitis]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Mononucleosis|Infectious mononucleosis]]<ref name="pmid21191775">{{cite journal |vauthors=Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL |title=Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China |journal=World J Pediatr |volume=7 |issue=1 |pages=45–9 |date=February 2011 |pmid=21191775 |doi=10.1007/s12519-011-0244-1 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Mononucleosis|Infectious mononucleosis]]<ref name="pmid21191775">{{cite journal |vauthors=Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL |title=Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China |journal=World J Pediatr |volume=7 |issue=1 |pages=45–9 |date=February 2011 |pmid=21191775 |doi=10.1007/s12519-011-0244-1 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Epstein Barr virus|EBV]]
* [[Epstein Barr virus|EBV]]
| align="center" style="background:#F5F5F5;" |More in children and young adults
| align="center" style="background:#F5F5F5;" |More in children and young adults
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Close contact
* Close contact
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 647: Line 643:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pharyngitis|Sore throat]]
* [[Pharyngitis|Sore throat]]
* Enlarged [[Tonsil|tonsils]]
* Enlarged [[Tonsil|tonsils]]
Line 664: Line 660:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Clinical manifestation + [[heterophile antibody test]]
| align="center" style="background:#F5F5F5;" |Clinical manifestation + [[heterophile antibody test]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Splenic rupture]]
* [[Splenic rupture]]
* [[Lymphocytosis]]
* [[Lymphocytosis]]
Line 670: Line 666:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Cytomegalovirus]]<ref name="pmid25308607">{{cite journal |vauthors=Smiechura M, Strużycka M, Konopka W |title=Congenital and acquired cytomegalovirus infection and hearing evaluation in children |journal=Otolaryngol Pol |volume=68 |issue=6 |pages=303–7 |date=2014 |pmid=25308607 |doi=10.1016/j.otpol.2014.04.003 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Cytomegalovirus]]<ref name="pmid25308607">{{cite journal |vauthors=Smiechura M, Strużycka M, Konopka W |title=Congenital and acquired cytomegalovirus infection and hearing evaluation in children |journal=Otolaryngol Pol |volume=68 |issue=6 |pages=303–7 |date=2014 |pmid=25308607 |doi=10.1016/j.otpol.2014.04.003 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Cytomegalovirus infection|CMV]]
* [[Cytomegalovirus infection|CMV]]
| align="center" style="background:#F5F5F5;" |More in immunocompromised patients and during pregnancy
| align="center" style="background:#F5F5F5;" |More in immunocompromised patients and during pregnancy
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Close contact
* Close contact
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 684: Line 680:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Exudative [[pharyngitis]]
* Exudative [[pharyngitis]]
* Symmetrical cervical [[Lymphadenopathy|adenopathy]]
* Symmetrical cervical [[Lymphadenopathy|adenopathy]]
Line 702: Line 698:
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Bacteria|Bacterial]]
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Bacteria|Bacterial]]
! align="center" style="background:#DCDCDC;" |[[Salmonella]]<ref name="pmid26068006">{{cite journal |vauthors=Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V |title=Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen |journal=PLoS ONE |volume=10 |issue=6 |pages=e0130092 |date=2015 |pmid=26068006 |pmc=4466801 |doi=10.1371/journal.pone.0130092 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Salmonella]]<ref name="pmid26068006">{{cite journal |vauthors=Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V |title=Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen |journal=PLoS ONE |volume=10 |issue=6 |pages=e0130092 |date=2015 |pmid=26068006 |pmc=4466801 |doi=10.1371/journal.pone.0130092 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Salmonella]]  
* [[Salmonella]]  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 975: Line 971:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation
! colspan="2" align="center" style="background:#DCDCDC;" |[[Sarcoidosis]]<ref name="pmid25473783">{{cite journal |vauthors=Modaresi Esfeh J, Culver D, Plesec T, John B |title=Clinical presentation and protocol for management of hepatic sarcoidosis |journal=Expert Rev Gastroenterol Hepatol |volume=9 |issue=3 |pages=349–58 |date=March 2015 |pmid=25473783 |doi=10.1586/17474124.2015.958468 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Sarcoidosis]]<ref name="pmid25473783">{{cite journal |vauthors=Modaresi Esfeh J, Culver D, Plesec T, John B |title=Clinical presentation and protocol for management of hepatic sarcoidosis |journal=Expert Rev Gastroenterol Hepatol |volume=9 |issue=3 |pages=349–58 |date=March 2015 |pmid=25473783 |doi=10.1586/17474124.2015.958468 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Immunity (medical)|Immune]] mediated
* [[Immunity (medical)|Immune]] mediated
* Unknown
* Unknown
| align="center" style="background:#F5F5F5;" |[[Autoimmune disease]], more in young African American women
| align="center" style="background:#F5F5F5;" |[[Autoimmune disease]], more in young African American women
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 990: Line 986:
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]]
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]]
* [[Blurred vision|Blurry vision]]
* [[Blurred vision|Blurry vision]]
Line 1,005: Line 1,001:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] on [[Chest X-ray|chest x-ray]]
* Bilateral [[Hilar lymphadenopathy|hilar adenopathy]] on [[Chest X-ray|chest x-ray]]
| align="center" style="background:#F5F5F5;" |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" |Diagnosis of exclusion
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Interstitial lung disease]]
* [[Interstitial lung disease]]
* Systemic [[Inflammation|inflammatory]]<nowiki/>disease
* Systemic [[Inflammation|inflammatory]]<nowiki/>disease
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Serum sickness]]<ref name="pmid26677148">{{cite journal |vauthors=Chiong FJ, Loewenthal M, Boyle M, Attia J |title=Serum sickness-like reaction after influenza vaccination |journal=BMJ Case Rep |volume=2015 |issue= |pages= |date=December 2015 |pmid=26677148 |pmc=4691861 |doi=10.1136/bcr-2015-211917 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Serum sickness]]<ref name="pmid26677148">{{cite journal |vauthors=Chiong FJ, Loewenthal M, Boyle M, Attia J |title=Serum sickness-like reaction after influenza vaccination |journal=BMJ Case Rep |volume=2015 |issue= |pages= |date=December 2015 |pmid=26677148 |pmc=4691861 |doi=10.1136/bcr-2015-211917 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Immune complex [[hypersensitivity]] (type III) to certain medications
* Immune complex [[hypersensitivity]] (type III) to certain medications
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Consumption of certain medications
* Consumption of certain medications
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 1,027: Line 1,023:
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Rash|Rashes]]
* [[Rash|Rashes]]
* [[Itch|Itching]]
* [[Itch|Itching]]
Line 1,042: Line 1,038:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Proteinuria]]
* [[Proteinuria]]
* [[Hematuria]]
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Plasma cell|Plasma cells]] on peripheral blood smear
* [[Plasma cell|Plasma cells]] on peripheral blood smear
* Numerous histological changes including [[inflammation]] of arterial wall or [[fibrosis]]
* Numerous histological changes including [[inflammation]] of arterial wall or [[fibrosis]]
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |Clinical manifestation + recent medication consumption
| align="center" style="background:#F5F5F5;" |Clinical manifestation + recent medication consumption
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Glomerular disease|Glomerulonephritis]]
* [[Glomerular disease|Glomerulonephritis]]
* [[Shock]]
* [[Shock]]
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]<ref name="pmid24461385">{{cite journal |vauthors=Yu C, Gershwin ME, Chang C |title=Diagnostic criteria for systemic lupus erythematosus: a critical review |journal=J. Autoimmun. |volume=48-49 |issue= |pages=10–3 |date=2014 |pmid=24461385 |doi=10.1016/j.jaut.2014.01.004 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Systemic lupus erythematosus]]<ref name="pmid24461385">{{cite journal |vauthors=Yu C, Gershwin ME, Chang C |title=Diagnostic criteria for systemic lupus erythematosus: a critical review |journal=J. Autoimmun. |volume=48-49 |issue= |pages=10–3 |date=2014 |pmid=24461385 |doi=10.1016/j.jaut.2014.01.004 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
| align="center" style="background:#F5F5F5;" |More in young females
| align="center" style="background:#F5F5F5;" |More in young females
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 1,069: Line 1,065:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Rash|Skin rash]]
* [[Rash|Skin rash]]
* [[Oral ulcer|Mouth ulcers]]
* [[Oral ulcer|Mouth ulcers]]
Line 1,081: Line 1,077:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Hemoglobinuria]]
* [[Hemoglobinuria]]
* [[Proteinuria]]
* [[Proteinuria]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Hypocellular [[bone marrow]]
* Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies
| align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Multi organ damage
* Multi organ damage
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]]<ref name="pmid24472276">{{cite journal |vauthors=Huang T, Liu M, Xu G |title=Felty's syndrome with hyperthyroidism: a case report and literature review |journal=Int J Rheum Dis |volume=17 |issue=1 |pages=122–4 |date=January 2014 |pmid=24472276 |doi=10.1111/1756-185X.12117 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Felty's syndrome|Felty syndrome]]<ref name="pmid24472276">{{cite journal |vauthors=Huang T, Liu M, Xu G |title=Felty's syndrome with hyperthyroidism: a case report and literature review |journal=Int J Rheum Dis |volume=17 |issue=1 |pages=122–4 |date=January 2014 |pmid=24472276 |doi=10.1111/1756-185X.12117 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
* Immune mediated [[Bone marrow suppression|bone marrow failure]]
| align="center" style="background:#F5F5F5;" |Rare [[autoimmune disease]], more in females 50-70 years old
| align="center" style="background:#F5F5F5;" |Rare [[autoimmune disease]], more in females 50-70 years old
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* History of [[rheumatoid arthritis]]
* History of [[rheumatoid arthritis]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 1,106: Line 1,102:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Pallor]]
* [[Pallor]]
* [[Hyperpigmentation|Skin hyperpigmentation]]
* [[Hyperpigmentation|Skin hyperpigmentation]]
* Painful, stiff, and swollen [[Joint|joints]]
* Painful, stiff, and swollen [[Joint|joints]]
* [[Keratoconjunctivitis sicca]]
* [[Keratoconjunctivitis sicca]]
Line 1,120: Line 1,115:
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Hypocellular [[bone marrow]]
* Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies
| align="center" style="background:#F5F5F5;" |Clinical findings + laboratory studies
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Rheumatoid arthritis]]
* [[Rheumatoid arthritis]]
* [[Infection|Infections]]
* [[Infection|Infections]]
Line 1,157: Line 1,152:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Gaucher's disease|Gaucher disease]]<ref name="pmid23510067">{{cite journal |vauthors=Ayto R, Hughes DA |title=Gaucher disease and myeloma |journal=Crit Rev Oncog |volume=18 |issue=3 |pages=247–68 |date=2013 |pmid=23510067 |doi= |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Gaucher's disease|Gaucher disease]]<ref name="pmid23510067">{{cite journal |vauthors=Ayto R, Hughes DA |title=Gaucher disease and myeloma |journal=Crit Rev Oncog |volume=18 |issue=3 |pages=247–68 |date=2013 |pmid=23510067 |doi= |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Accumulatio<nowiki/>n of [[glucocerebroside]]
* Accumulatio<nowiki/>n of [[glucocerebroside]]
| align="center" style="background:#F5F5F5;" |[[Autosomal recessive]] hereditary deficiency of the enzyme [[glucocerebrosidase]], more in Ashkenazi Jews
| align="center" style="background:#F5F5F5;" |[[Autosomal recessive]] hereditary deficiency of the enzyme [[glucocerebrosidase]], more in Ashkenazi Jews
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
Line 1,171: Line 1,166:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Painful [[bone]] lesions
* Painful [[bone]] lesions
* [[Lymphadenopathy]]
* [[Lymphadenopathy]]
Line 1,182: Line 1,177:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Proteinuria]]
* [[Proteinuria]]
* [[Hematuria]]
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Hypocellular [[bone marrow]]
* Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |[[Enzyme]] testing
| align="center" style="background:#F5F5F5;" |[[Enzyme]] testing
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* The most common of the [[Lysosomal storage disease|lysosomal storage diseases]]
* The most common of the [[Lysosomal storage disease|lysosomal storage diseases]]
* Severe neurological complications
* Severe neurological complications
Line 1,196: Line 1,191:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Niemann-Pick disease]]<ref name="pmid23622394">{{cite journal |vauthors=Vanier MT |title=Niemann-Pick diseases |journal=Handb Clin Neurol |volume=113 |issue= |pages=1717–21 |date=2013 |pmid=23622394 |doi=10.1016/B978-0-444-59565-2.00041-1 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Niemann-Pick disease]]<ref name="pmid23622394">{{cite journal |vauthors=Vanier MT |title=Niemann-Pick diseases |journal=Handb Clin Neurol |volume=113 |issue= |pages=1717–21 |date=2013 |pmid=23622394 |doi=10.1016/B978-0-444-59565-2.00041-1 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Mutations in the ''[[Sphingomyelin phosphodiesterase 1|SMPD1]]'' gene
* Mutations in the ''[[Sphingomyelin phosphodiesterase 1|SMPD1]]'' gene
* Deficiency in the activity of the lysosomal enzyme acid [[sphingomyelinase]]
* Deficiency in the activity of the lysosomal enzyme acid [[sphingomyelinase]]
* Accumulation of [[sphingomyelin]]
* Accumulation of [[sphingomyelin]]
| align="center" style="background:#F5F5F5;" |[[Autosomal recessive]] [[lysosomal storage disease]], more in Ashkenazi Jews
| align="center" style="background:#F5F5F5;" |[[Autosomal recessive]] [[lysosomal storage disease]], more in Ashkenazi Jews
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Positive family history
* Positive family history
| align="center" style="background:#F5F5F5;" | -
| align="center" style="background:#F5F5F5;" | -
Line 1,212: Line 1,207:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Ataxia|Unsteady gait]]
* [[Ataxia|Unsteady gait]]
* Slurred [[speech]]
* Slurred [[speech]]
Line 1,224: Line 1,219:
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |↑
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Proteinuria]]
* [[Proteinuria]]
* [[Hematuria]]
* [[Hematuria]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* Hypocellular [[bone marrow]]
* Hypocellular [[bone marrow]]
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |NA
| align="center" style="background:#F5F5F5;" |[[Genetic testing]]
| align="center" style="background:#F5F5F5;" |[[Genetic testing]]
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[CNS]] involvement
* [[CNS]] involvement
* [[Supranuclear ocular palsy|Supranuclear gaze palsy]]
* [[Supranuclear ocular palsy|Supranuclear gaze palsy]]
Line 1,242: Line 1,237:
|-
|-
! colspan="2" align="center" style="background:#DCDCDC;" |[[Amyloidosis]]<ref name="pmid26230754">{{cite journal |vauthors=Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S |title=Amyloidosis: Modern Cross-sectional Imaging |journal=Radiographics |volume=35 |issue=5 |pages=1381–92 |date=2015 |pmid=26230754 |doi=10.1148/rg.2015140179 |url=}}</ref>
! colspan="2" align="center" style="background:#DCDCDC;" |[[Amyloidosis]]<ref name="pmid26230754">{{cite journal |vauthors=Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S |title=Amyloidosis: Modern Cross-sectional Imaging |journal=Radiographics |volume=35 |issue=5 |pages=1381–92 |date=2015 |pmid=26230754 |doi=10.1148/rg.2015140179 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="left" style="background:#F5F5F5;" |
* [[Protein]] misfolding
* [[Protein]] misfolding
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |

Revision as of 19:15, 5 October 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2], Gichoya Judy Wawira [3],

Synonyms and keywords: Spleen enlargement; enlarged spleen; spleen swelling

Differentiating Splenomegaly from Other Diseases

Category Disease Etiology Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs Lab Findings Imaging
Fever Fatigue Weight Abdominal pain Bleeding BP JVP Jaundice Ascites Other CBC Iron LFT PT/PTT BUN/Cr UA Histopathology
WBC Hb Plt
Congestive Cirrhosis[1] Any, more in elderly + ↑↓ + + Nl + + Nl Liver biopsy
Heart failure[2] Elderly + ↑↓ ± + Nl Nl NA Echocardiography
Thrombosis of portal, hepatic, or splenic veins[3] Any + + + + Nl ± + Nl NA Doppler ultrasonography
Malignancy Lymphoma[4] Any, most common malignant splenic tumor + + + + Nl Nl + High ferritin Nl Lymph node biopsy
Leukemia[5] Elderly, male>female + + + + Nl Nl ± + High ferritin Nl
  • Leukemic blasts
  • Leukoerythroblastic features
  • Giant platelets
NA Bone marrow examination + clinical manifestation
Polycythemia Vera[6] Mean age >60 years old
  • Positive family history
+ Nl + Nl Nl Nl to ↑ Nl to ↑ High ferritin Nl Nl Nl Nl
  • Elevated normochromic, normocytic RBCs
  • Thrombocytosis
  • Rarely immature cells
  • Leukoerythroblastic picture
NA WHO criteria for PV
Disease Etiology Demography History Fever Fatigue Weight loss Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Multiple myeloma[7] Any, more in adults + + + + Nl Nl + High ferritin Nl
  • Blast cells
Bone marrow examination
Essential thrombocythemia[8]
  • Acquired mutation of JAK2, CALR, or MPL
Mean age >60 years old, female > male ± + Nl + + Nl Nl ↑↑ Nl Nl Nl Nl Nl Bone marrow biopsy
Primary myelofibrosis[9] Mean age >60 years old, male> female + Nl + + Nl Nl + ↑/↓ Low iron Nl Nl Bone marrow biopsy
Primary splenic tumors[10] Very rare
  • Positive family history
+ + + Nl Nl
  • Lymphadenopathy
  • Dyspnea
  • Shoulder pain
  • Constipation
  • Cachexia
  • Pleural infusion
Low iron, low ferritin
  • Different histopathologic features depends on the type of tumor
Biopsy
Metastatic solid tumors[11] Any, more in adults + + + + Nl ± ± Low iron, high ferritin
  • Blast cells
Biopsy
Disease Etiology Demography History Fever Fatigue Weight Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Infection Viral Hepatitis[12] Any
  • High risk behaviors
  • Close contact
+ + + + Nl Nl + + Nl Clinical manifestation + lab tests
Infectious mononucleosis[13] More in children and young adults
  • Close contact
+ + Nl + Nl Nl + Nl Nl Nl Nl Nl NA Clinical manifestation + heterophile antibody test
Cytomegalovirus[14] More in immunocompromised patients and during pregnancy
  • Close contact
+ + Nl + Nl Nl + Nl Nl Nl Nl Nl NA ELISA
Bacterial Salmonella[15]
Brucella[16]
Tuberculosis[17]
Parasitic Malaria[18]
Schistosomiasis[19]
Toxoplasmosis[20]
Kala-azar[21] Visceral leishmaniasis
Infective endocarditis[22]
Fungal[23]
Disease Etiology Demography History Fever Fatigue Weight loss Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Inflammation Sarcoidosis[24] Autoimmune disease, more in young African American women
  • Positive family history
+ + + + Nl Nl Nl Nl Nl Nl Nl NA Diagnosis of exclusion
Serum sickness[25] Any
  • Consumption of certain medications
+ + Nl + Nl ↓ or ↑

Eosinophilia

Nl Nl Nl NA Clinical manifestation + recent medication consumption
Systemic lupus erythematosus[26] More in young females
  • Positive family history
+ + + + Nl to ↓ Nl + + Clinical findings + laboratory studies
  • Multi organ damage
Felty syndrome[27] Rare autoimmune disease, more in females 50-70 years old + + + + Nl to ↓ Nl + + Nl Nl Nl Nl Nl Clinical findings + laboratory studies
Infiltrative Disease Etiology Demography History Fever Fatigue Weight Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings
Gaucher disease[28] Autosomal recessive hereditary deficiency of the enzyme glucocerebrosidase, more in Ashkenazi Jews
  • Positive family history
- + + + Nl to ↓ Nl + + Nl Nl NA Enzyme testing
Niemann-Pick disease[29] Autosomal recessive lysosomal storage disease, more in Ashkenazi Jews
  • Positive family history
- + + + Nl to ↓ Nl + + Nl NA Genetic testing
Amyloidosis[30]
Langerhans cell histiocytosis[31]
Hemophagocytic lymphohistiocytosis[32]
Rosai-Dorfman disease[33]
Hematologic (hypersplenic) states Hemolytic anemia[34]
Sickle cell disease[35]
Granulocyte colony-stimulating factor[36]
Disease Etiology Demography History Fever Fatigue Weight loss Abdominal pain Bleeding BP JVP Jaundice Ascites Other WBC Hb Plt Iron LFT PT/PTT BUN/Cr UA Histopathology Imaging Gold standard Associated findings

References

  1. Wu Z, Zhou J, Pankaj P, Peng B (December 2012). "Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity". Surg Endosc. 26 (12): 3557–64. doi:10.1007/s00464-012-2366-5. PMID 22710653.
  2. Gedela M, Khan M, Jonsson O (September 2015). "Heart Failure". S D Med. 68 (9): 403–5, 407–9. PMID 26489162.
  3. Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ (2012). "Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center". Arq Gastroenterol. 49 (1): 69–76. PMID 22481689.
  4. Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y (May 2015). "Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma". Hematology. 20 (4): 203–7. doi:10.1179/1607845414Y.0000000192. PMID 25131182.
  5. Quest GR, Johnston JB (December 2015). "Clinical features and diagnosis of hairy cell leukemia". Best Pract Res Clin Haematol. 28 (4): 180–92. doi:10.1016/j.beha.2015.10.017. PMID 26614896.
  6. Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH (March 2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur. J. Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
  7. Grieco A, Manna R, Mancini R, Gambassi G (April 1988). "Massive hepatomegaly following splenectomy for myeloid metaplasia". Am. J. Med. 84 (4): 797. PMID 3400674.
  8. Tefferi A, Barbui T (February 2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am. J. Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
  9. Cervantes F, Martinez-Trillos A (May 2013). "Myelofibrosis: an update on current pharmacotherapy and future directions". Expert Opin Pharmacother. 14 (7): 873–84. doi:10.1517/14656566.2013.783019. PMID 23514013.
  10. Adachi K, Ui M, Nojima H, Takada Y, Enatsu K (August 2011). "Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy". Am. J. Surg. 202 (2): e17–9. doi:10.1016/j.amjsurg.2010.10.002. PMID 21810495.
  11. Huprikar NA, Kurtz MT, Mount CA (October 2013). "Massive splenomegaly and lymphopenia: a unique case of obstructive shock". BMJ Case Rep. 2013. doi:10.1136/bcr-2013-201643. PMC 3822246. PMID 24172780.
  12. Kumar KJ, Kumar HC, Manjunath VG, Anitha C, Mamatha S (January 2014). "Hepatitis A in children- clinical course, complications and laboratory profile". Indian J Pediatr. 81 (1): 15–9. doi:10.1007/s12098-013-1114-8. PMID 23904062.
  13. Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL (February 2011). "Epidemiologic and clinical characteristics of infectious mononucleosis associated with Epstein-Barr virus infection in children in Beijing, China". World J Pediatr. 7 (1): 45–9. doi:10.1007/s12519-011-0244-1. PMID 21191775.
  14. Smiechura M, Strużycka M, Konopka W (2014). "Congenital and acquired cytomegalovirus infection and hearing evaluation in children". Otolaryngol Pol. 68 (6): 303–7. doi:10.1016/j.otpol.2014.04.003. PMID 25308607.
  15. Rosche KL, Aljasham AT, Kipfer JN, Piatkowski BT, Konjufca V (2015). "Infection with Salmonella enterica Serovar Typhimurium Leads to Increased Proportions of F4/80+ Red Pulp Macrophages and Decreased Proportions of B and T Lymphocytes in the Spleen". PLoS ONE. 10 (6): e0130092. doi:10.1371/journal.pone.0130092. PMC 4466801. PMID 26068006.
  16. Roset MS, Ibañez AE, de Souza Filho JA, Spera JM, Minatel L, Oliveira SC, Giambartolomei GH, Cassataro J, Briones G (2014). "Brucella cyclic β-1,2-glucan plays a critical role in the induction of splenomegaly in mice". PLoS ONE. 9 (7): e101279. doi:10.1371/journal.pone.0101279. PMC 4077732. PMID 24983999.
  17. Chandni R, Chandni R, Chandni R (2016). "Extra pulmonary tuberculosis presenting as fever with massive splenomegaly and pancytopenia". IDCases. 4: 20–2. doi:10.1016/j.idcr.2016.02.005. PMC 4802818. PMID 27051579.
  18. Sumbele IU, Bopda OS, Kimbi HK, Ning TR, Nkuo-Akenji T (November 2015). "Influence of Plasmodium gametocyte carriage on the prevalence of fever, splenomegaly and cardiovascular parameters in children less than 15 years in the Mount Cameroon area: cross sectional study". BMC Infect. Dis. 15: 547. doi:10.1186/s12879-015-1290-4. PMC 4661959. PMID 26612502.
  19. Pan J, Liu L, Yan YH, Shao ZW, Li Q, Zhou RH (August 2014). "[Application of health education path in advanced schistosomiasis patients with splenomegaly in perioperative period]". Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi (in Chinese). 26 (4): 425–7, 430. PMID 25434143.
  20. Oz HS (August 2014). "Novel Synergistic Protective Efficacy of Atovaquone and Diclazuril on Fetal-Maternal Toxoplasmosis". Int J Clin Med. 5 (15): 921–932. PMC 4157831. PMID 25210646.
  21. Sayyahfar S, Ansari S, Mohebali M, Behnam B (April 2014). "Visceral leishmaniasis without fever in an 11-month-old infant: a rare clinical feature of Kala-azar". Korean J. Parasitol. 52 (2): 189–91. doi:10.3347/kjp.2014.52.2.189. PMC 4028457. PMID 24850963.
  22. Francischetto O, Silva LA, Senna KM, Vasques MR, Barbosa GF, Weksler C, Ramos RG, Golebiovski WF, Lamas Cda C (October 2014). "Healthcare-associated infective endocarditis: a case series in a referral hospital from 2006 to 2011". Arq. Bras. Cardiol. 103 (4): 292–8. PMC 4206359. PMID 25352503.
  23. Balakrishnan N, Jawanda JS, Miller MB, Breitschwerdt EB (February 2013). "Bartonella henselae infection in a man with hypergammaglobulinaemia, splenomegaly and polyclonal plasmacytosis". J. Med. Microbiol. 62 (Pt 2): 338–41. doi:10.1099/jmm.0.052134-0. PMID 23118473.
  24. Modaresi Esfeh J, Culver D, Plesec T, John B (March 2015). "Clinical presentation and protocol for management of hepatic sarcoidosis". Expert Rev Gastroenterol Hepatol. 9 (3): 349–58. doi:10.1586/17474124.2015.958468. PMID 25473783.
  25. Chiong FJ, Loewenthal M, Boyle M, Attia J (December 2015). "Serum sickness-like reaction after influenza vaccination". BMJ Case Rep. 2015. doi:10.1136/bcr-2015-211917. PMC 4691861. PMID 26677148.
  26. Yu C, Gershwin ME, Chang C (2014). "Diagnostic criteria for systemic lupus erythematosus: a critical review". J. Autoimmun. 48-49: 10–3. doi:10.1016/j.jaut.2014.01.004. PMID 24461385.
  27. Huang T, Liu M, Xu G (January 2014). "Felty's syndrome with hyperthyroidism: a case report and literature review". Int J Rheum Dis. 17 (1): 122–4. doi:10.1111/1756-185X.12117. PMID 24472276.
  28. Ayto R, Hughes DA (2013). "Gaucher disease and myeloma". Crit Rev Oncog. 18 (3): 247–68. PMID 23510067.
  29. Vanier MT (2013). "Niemann-Pick diseases". Handb Clin Neurol. 113: 1717–21. doi:10.1016/B978-0-444-59565-2.00041-1. PMID 23622394.
  30. Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S (2015). "Amyloidosis: Modern Cross-sectional Imaging". Radiographics. 35 (5): 1381–92. doi:10.1148/rg.2015140179. PMID 26230754.
  31. DiCaprio MR, Roberts TT (October 2014). "Diagnosis and management of langerhans cell histiocytosis". J Am Acad Orthop Surg. 22 (10): 643–52. doi:10.5435/JAAOS-22-10-643. PMID 25281259.
  32. Filipovich AH, Chandrakasan S (October 2015). "Pathogenesis of Hemophagocytic Lymphohistiocytosis". Hematol. Oncol. Clin. North Am. 29 (5): 895–902. doi:10.1016/j.hoc.2015.06.007. PMID 26461149.
  33. Hashimoto K, Kariya S, Onoda T, Ooue T, Yamashita Y, Naka K, Okano M, Nishizaki K (March 2014). "Rosai-Dorfman disease with extranodal involvement". Laryngoscope. 124 (3): 701–4. doi:10.1002/lary.24290. PMID 23818241.
  34. Hill QA (October 2015). "Autoimmune hemolytic anemia". Hematology. 20 (9): 553–4. doi:10.1179/1024533215Z.000000000401. PMID 26447931.
  35. Gravitz L, Pincock S (November 2014). "Sickle-cell disease". Nature. 515 (7526): S1. doi:10.1038/515S1a. PMID 25390134.
  36. Abraham I, Tharmarajah S, MacDonald K (March 2013). "Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors". Expert Opin Drug Saf. 12 (2): 235–46. doi:10.1517/14740338.2013.770472. PMID 23419039.